智通财经APP获悉，2025年4月25日至30日，美国癌症研究协会 (AACR)年会于芝加哥召开。基石药业 (02616) ...

CStone will showcase its latest preclinical studies on five internally developed innovative candidates, including the trispecific antibody CS2009, the bispecific antibody CS2011, and three novel ...

a bispecific antibody. This indicates that trispecific antibodies may provide a more thorough approach to combating disease by activating additional pathways or immune responses. The capability to ...

Building on this foundation, bispecific and trispecific antibodies have emerged ... with the bispecific antibody market estimated at around US$ 12 billion in 2024. Projections from KuicK Research ...

CStone will showcase its latest preclinical studies on five internally developed innovative candidates, including the trispecific antibody CS2009, the bispecific antibody CS2011, and three novel ...

The company has 51 applications pending at various stages in the approval process. ETMarkets.com ISB 2001, a trispecific antibody, which aims to treat multiple myeloma, a type of blood cancer, may ...

These include the trispecific antibody CS2009 and several ADCs developed from CStone’s proprietary platform. The showcased candidates demonstrate potential for enhanced anti-tumor efficacy and ...

“Among these, we are excited to share updates on ZW209, our DLL3-targeting trispecific T cell engager incorporating co-stimulation, which is on track for IND submission in 1H-2026, and ZW327, our Ly6E ...

Building on this foundation, bispecific and trispecific antibodies have emerged as innovative biologics aimed at ... The success of these agents is evident in market valuations, with the bispecific ...